Compliance Agreements: the Monitor Who Moves in for Years

The most significant practical difference between a deferred prosecution agreement and a non-prosecution agreement is what happens in open court, and that difference affects the company's exposure to public scrutiny, judicial oversight, and collateral litigation.

A DPA requires that a criminal information be filed in federal court and that the agreement be submitted to the court for approval. The judge can scrutinize the terms, reject the agreement, and impose additional conditions. The filed criminal information becomes a public document that plaintiffs' counsel in parallel civil litigation can use to establish facts the company has already admitted. An NPA is a private agreement between the company and DOJ that requires no court filing, no judicial approval, and no public criminal charge, giving both parties more confidentiality but leaving the monitor's authority entirely in the government's hands without any judicial check.

The preference between DPA and NPA from the company's perspective depends entirely on the facts: when the company needs judicial oversight to prevent the monitor from overreaching, a DPA's court involvement is protective; when the company's primary concern is keeping the resolution out of the public record, the NPA's private structure is more valuable. An attorney who handles corporate compliance and DOJ resolution negotiations can evaluate which structure provides more protection given the specific facts of the investigation and the industry context.

A compliance agreement's stated duration is the minimum, not the guarantee, and the conditions that trigger an extension are typically within the monitor's authority to identify rather than requiring the government to find a formal breach.

Extension triggers most commonly include a monitor's finding that the compliance program has not been fully implemented by a defined milestone, the discovery of a new compliance violation during the monitoring period that is related to the conduct underlying the original investigation, or the company's failure to implement a monitor recommendation within the agreed response period. Each of these triggers can be satisfied by conditions that the company might view as minor and the monitor views as material, and the resolution of that disagreement favors the monitor because the DOJ typically defers to monitor findings when extension decisions are made.

The most reliable mechanism for preventing extensions is demonstrating measurable compliance improvement from the first reporting period, before the monitor has established a pattern of finding problems. A company that enters the monitoring period with a fully documented, tested, and operational compliance program demonstrating pre-agreement remediation leaves the monitor with less to find. An attorney who handles compliance audit and monitoring response matters can build the evidentiary record of compliance effectiveness before the monitor's first assessment.

A compliance monitor who identifies a new violation during the monitoring period can trigger both an extension of the agreement and a new DOJ investigation of the newly discovered conduct. The new investigation proceeds under the existing cooperation and disclosure obligations of the DPA, meaning the company must report the new conduct to DOJ before it has fully investigated the scope of the problem internally. The interaction between the ongoing disclosure obligation and a newly discovered compliance failure is among the most operationally dangerous aspects of life under a compliance agreement.

A company that discovers a potential violation and voluntarily discloses it to the DOJ before the government has independently developed substantial evidence enters the resolution negotiation from a fundamentally stronger position than one that is approached by the government first.

DOJ's Corporate Enforcement and Voluntary Self-Disclosure Policy creates an explicit pathway for companies that self-disclose, fully cooperate, and remediate the underlying conduct to receive a declination of prosecution in all but the most exceptional circumstances. Even when prosecution is not declined, a company that self-discloses receives a reduced penalty, typically a 50 percent reduction from the low end of the applicable guideline range, and may avoid mandatory monitorship entirely if the existing compliance program was effective and the violation was isolated rather than systemic.

The timing of self-disclosure is the mechanism that determines which framework applies. A company that discovers a violation and discloses before any government inquiry has begun is in the best position. A company that discloses after receiving a government subpoena has lost most of the self-disclosure benefit. A company that discloses after learning the government has already interviewed witnesses or executed a search warrant receives essentially no self-disclosure credit. An attorney who handles SEC compliance and DOJ voluntary disclosure matters can evaluate whether a specific potential violation qualifies for the self-disclosure framework and advise on the disclosure timing that maximizes the benefit before the government's investigation makes it unavailable.

Healthcare companies operating under Corporate Integrity Agreements face a specific version of the ongoing disclosure risk. A CIA requires the company to notify the OIG within 30 days of discovering a reportable event, which includes any credible evidence of a federal healthcare program violation. An internal audit that identifies a billing irregularity triggers the 30-day clock regardless of whether the company has completed its internal investigation or determined the scope of the problem. Companies under CIAs must design their internal investigation process to produce a preliminary reportable event determination within the 30-day window or risk an OIG finding of CIA breach for late disclosure.

A compliance agreement is a negotiated resolution between a company and a government enforcement agency that avoids criminal prosecution or regulatory penalties in exchange for defined compliance obligations, financial penalties, and an independent monitor who operates inside the company for the agreement's duration. The company does not plead guilty, but it admits facts in a statement of facts attached to the agreement, pays a financial penalty calculated under the Federal Sentencing Guidelines, and submits to years of external review during which the monitor reports findings directly to the government. The agreement's terms define the monitor's scope, the duration of the monitoring period, and the conditions that can extend it.

The independent compliance monitor is a third-party professional appointed under the compliance agreement, typically a former DOJ official, former regulator, or senior compliance attorney, who has contractual authority to review the company's compliance program and operations. The monitor's specific access rights are defined in the agreement but typically include the right to review financial records, interview employees at any level without advance management notice, review internal audit reports, and access privileged communications where privilege has been waived. The monitor reports findings directly to DOJ without first obtaining company approval, and those reports can trigger extensions of the monitoring period or new government investigations.

Yes. Compliance agreement extension provisions typically allow DOJ to extend the monitoring period when the monitor identifies that compliance milestones have not been met, when a new violation is discovered during monitoring, or when the company fails to implement monitor recommendations on schedule. The extension decision is made by the government based on the monitor's reports, not by renegotiation with the company. Building compliance infrastructure that demonstrates measurable progress from the first reporting period is the most reliable mechanism for keeping the monitoring period to its contractually agreed term.

A deferred prosecution agreement requires the government to file criminal charges in court, submit the agreement for judicial approval, and create a public court record. The court can scrutinize the agreement's terms and impose additional conditions. A non-prosecution agreement is a private arrangement in which no charges are filed, no court approval is required, and no public criminal record is created. A DPA's court involvement provides a check on monitor overreach through judicial oversight; an NPA's privacy prevents the public criminal record from being used in parallel civil litigation. The better structure depends on whether the company's greater risk is monitor overreach or collateral civil litigation from the disclosed facts.

Self-disclosure before the government has independently developed substantial evidence of the violation is the single most powerful factor in reducing the terms of any compliance agreement. Under DOJ's Corporate Enforcement and Voluntary Self-Disclosure Policy, a company that self-discloses, fully cooperates, and remediates may receive a declination of prosecution entirely. When prosecution is not declined, self-disclosure typically produces a 50 percent penalty reduction from the guideline low end and may eliminate the mandatory monitorship requirement entirely for companies with effective existing compliance programs. A company that discloses after receiving a government subpoena has lost most of this benefit. An attorney who handles government regulatory compliance and DOJ voluntary disclosure matters can evaluate the disclosure timing that maximizes the available benefit.

A Corporate Integrity Agreement is an agreement with the HHS Office of Inspector General that serves as an alternative to exclusion from federal healthcare programs following settlement of a False Claims Act or anti-kickback investigation. Unlike a DPA, a CIA involves no criminal charges and is negotiated with the OIG rather than the DOJ. CIAs typically last five years and require the company to retain an Independent Review Organization to conduct annual audits of billing practices and referral arrangements, submitting annual reports to the OIG. CIAs also require notification to the OIG within 30 days of discovering a reportable event, which includes any credible evidence of a federal healthcare program violation. An attorney who handles healthcare compliance and CIA negotiation matters can evaluate which CIA terms exceed what comparable companies have accepted in OIG's published model CIAs.